<DOC>
	<DOCNO>NCT00235859</DOCNO>
	<brief_summary>The purpose study assess safety efficacy adalimumab compare placebo subject rheumatoid arthritis methotrexate therapy .</brief_summary>
	<brief_title>Adalimumab Administered Korean Rheumatoid Arthritis Subjects Treated With Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Meet ACR criterion diagnosis active RA &gt; 6 swollen joint &gt; 9 tender joint Subjects must receive least one prior DMARD besides MTX , may efficacy failure four standard DMARDs MTX Therapy MTX least 6 month prior screen stable dose MTX least 4 week prior screen visit Age 18 year old Prior treatment TNF antagonist , include adalimumab History clinically significant drug alcohol abuse previous year , iv drug abuse , active infection listeria tuberculosis ( TB ) , lymphoma leukemia , malignancy exception successfully treat nonmetastatic basalcell carcinoma skin . Subjects may administer live vaccine within three month prior study drug administration study , treatment investigational agent within 30 day 5 halflives agent , whichever longer , prior screen evaluation , treatment investigational biologic agent , include antiCD4 antibody , within 6 month prior screen evaluation , prior treatment TNF antagonist , include Adalimumab , prior exposure alkylating agent chlorambucil cyclophosphamide . Chest Xray calcify granuloma and/or pleural scar Positive TB skin test , RT23 dose skin test , &gt; 5 mm 48 72 hour Unstable ischemic heart disease , active inflammatory bowel disease , active peptic ulcer disease , recent stroke ( within 3 month screen evaluation ) poorly control medical condition Intraarticular , intramuscular iv administration corticosteroid within 4 week prior screen evaluation Female pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>adalimumab</keyword>
</DOC>